U.S. UROLOGY CLINICIAN SURVEY

277 Pages | 138 Exhibits | 2002 Analysis Product Family: Market Reports




OVERVIEW:
This survey report provides clients with primary research data obtained from more than 100 urologists in solo, group, and multi-specialty practices located throughout the country.

For this survey, urologists discussed their current and planned use of existing and emerging urology products and procedures; rated the efficacy of, and their familiarity with, selected urology products and procedures; assessed obstacles to the adoption of new technologies; and evaluated developments impacting urologic practice.

This report contains more than 130 exhibits and provides in-depth analysis of specific findings, which are broken down by urologist age group, patient volumes, and practice type and geographical location.

Major topics include: benign prostate disorder management; current and planned ownership of transrectal ultrasound equipment; current and planned ownership of urodynamic measurement systems; erectile dysfunction management; female urinary incontinence management; potential clinical value of urethral stents within the urology practice; prostate cancer management; types of patients treated with oral erectile dysfunction drugs; and urologists' perceptions of selected urology products companies.

TABLE OF CONTENTS:
OVERVIEW OF MAJOR SURVEY FINDINGS

     i. Respondent Profiles
     ii. Benign Prostate Disorder Management
     iii. Female Urinary Incontinence Management
     iv. Prostate Cancer Management
     v. Erectile Dysfunction Management
     vi. Developments Impacting Urologic Practice

1. RESPONDENT PROFILES

1.1 Survey Respondents
	1.1.1 Respondents, By Age Group
        1.1.2 Respondents, By Region
        1.1.3 Respondents, by Practice Type
        1.1.4 Respondents, by Practice Ownership
        1.1.5 Respondents, by Patient Volumes and Caseload Groups
        1.1.6 Respondents, by Practice Distribution

Exhibit 1-1: Distribution of the General United States Urologist Population and Survey Respondents, by Age Group
Exhibit 1-2: Distribution of the General United States Urologist Population and Survey Respondents, by Geographic Region
Exhibit 1-3: Survey Respondents, by Practice Type 
Exhibit 1-4: Survey Respondents, by Age Group and Practice Type 
Exhibit 1-5: Distribution of Survey Respondents, by Practice Ownership 
Exhibit 1-6: Weekly Patient Volumes, All Survey Respondents 
Exhibit 1-7: Weekly Patient Volumes, by Survey Respondent Age 
Exhibit 1-8: Weekly Patient Volumes, by Practice Type 
Exhibit 1-9: Distribution of Survey Respondents, by Patient Caseload Group 
Exhibit 1-10: Distribution of Survey Respondents, by Respondent Age and Patient Caseload Group 
Exhibit 1-11: Distribution of Survey Respondents, by Practice Type and Patient Caseload Group 
Exhibit 1-12: Average Practice Distribution, All Respondents 
Exhibit 1-13: 2001, Average Practice Distribution, By Respondent Age 
Exhibit 1-14: 2001, Average Practice Distribution, by Practice Type 
Exhibit 1-15: 2001, Average Practice Distribution, By Patient Volumes 
Exhibit 1-16: 2001, Average Practice Distribution, by Geographical Region 

2. BENIGN PROSTATE DISORDER MANAGEMENT

2.1 Benign Prostatic Hyperplasia Symptoms at Presentation
2.2 Effectiveness of Benign Prostatic Hyperplasia Treatments
2.3 Familiarity with Benign Prostatic Hyperplasia Treatments
2.4 Current and Planned Use of Emerging Benign Prostatic Hyperplasia Therapies
	2.4.1 Current and Planned Use of Transurethral Microwave Thermal Therapy
	2.4.2 Current and Planned Use of Transurethral Radiofrequency Needle Ablation
	2.4.3 Current and Planned Use of Holmium Laser Resection of the Prostate
	2.4.4 Current and Planned Use of Photoselective Vaporization of the Prostate
	2.4.5 Other Benign Prostatic Hyperplasia Therapies
2.5 Obstacles to Expanded Use of Minimally Invasive Benign Prostatic Hyperplasia Therapies
2.6 Potential Clinical Value of Short-Term Urethral Stents
2.7 Prostatitis Symptoms and Management

Exhibit 2-1: Severity of Patients' Benign Prostatic Hyperplasia Symptoms at Initial Presentation, All Survey Respondents 
Exhibit 2-2: Severity of Patients' Benign Prostatic Hyperplasia Symptoms at Initial Presentation, by Survey Respondent Age Group 
Exhibit 2-3: Severity of Patients' Benign Prostatic Hyperplasia Symptoms at Initial Presentation, by Practice Type 
Exhibit 2-4: Severity of Patients' Benign Prostatic Hyperplasia Symptoms at Initial Presentation, by Patient Volumes 
Exhibit 2-5: Severity of Patients' Benign Prostatic Hyperplasia Symptoms at Initial Presentation, by Geographical Region 
Exhibit 2-6: Rated Effectiveness of Benign Prostatic Hyperplasia Therapies, All Survey Respondents 
Exhibit 2-7: Rated Effectiveness of Benign Prostatic Hyperplasia Therapies, by Survey Respondent Age Group 
Exhibit 2-8: Rated Effectiveness of Benign Prostatic Hyperplasia Therapies, by Practice Type 
Exhibit 2-9: Rated Effectiveness of Benign Prostatic Hyperplasia Therapies, by Patient Volumes 
Exhibit 2-10: Rated Effectiveness of Benign Prostatic Hyperplasia Therapies, by Geographical Region 
Exhibit 2-11: Shares of Urologists Not Familiar with Emerging Benign Prostatic Hyperplasia Therapies, All Survey Respondents 
Exhibit 2-12: Shares of Urologists Not Familiar with Emerging Benign Prostatic Hyperplasia Therapies, by Survey Respondent Age Group 
Exhibit 2-13: Shares of Urologists Not Familiar with Emerging Benign Prostatic Hyperplasia Therapies, by Practice Type 
Exhibit 2-14: Shares of Urologists Not Familiar with Emerging Benign Prostatic Hyperplasia Therapies, by Patient Volumes 
Exhibit 2-15: Shares of Urologists Not Familiar with Emerging Benign Prostatic Hyperplasia Therapies, by Geographical Region 
Exhibit 2-16: Current and Planned Use of Emerging Benign Prostatic Hyperplasia Therapies, All Survey Respondents 
Exhibit 2-17: Current and Planned Use of Transurethral Microwave Thermal Therapy, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical Region 
Exhibit 2-18: Current and Planned Use of Transurethral Radiofrequency Needle Ablation, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical 
Region 
Exhibit 2-19: Current and Planned Use of Holmium Laser Resection of the Prostate, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical Region 
Exhibit 2-20: Current and Planned Use of Photoselective Vaporization of the Prostate, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical Region 
Exhibit 2-21: Obstacles to Widespread Adoption of Minimally Invasive Therapies for Benign Prostatic Hyperplasia, All Survey Respondents 
Exhibit 2-22: Factors Rated "Major Obstacle" to the Adoption of Minimally Invasive Benign Prostatic Hyperplasia Treatments, by Survey Respondent Age Group 
Exhibit 2-23: Factors Rated "Major Obstacle" to the Adoption of Minimally Invasive Benign Prostatic Hyperplasia Treatments, by Practice Type
Exhibit 2-24: Factors Rated "Major Obstacle" to the Adoption of Minimally Invasive Benign Prostatic Hyperplasia Treatments, by Patient Volumes
Exhibit 2-25: Factors Rated "Major Obstacle" to the Adoption of Minimally Invasive Benign Prostatic Hyperplasia Treatments, by Geographical Region 
Exhibit 2-26: Potential Clinical Value of Short-Term Urethral Stents Within the Urology Practice, All Survey Respondents 
Exhibit 2-27: Potential Clinical Value of Short-Term Urethral Stents Within the Urology Practice, by Survey Respondent Age Group 
Exhibit 2-28: Potential Clinical Value of Urethral Stents Within the Urology Practice, by Practice Type 
Exhibit 2-29: Potential Clinical Value of Urethral Stents Within the Urology Practice, by Patient Volumes 
Exhibit 2-30: Potential Clinical Value of Urethral Stents Within the Urology Practice, by Geographical Region 
Exhibit 2-31: Prostatitis Patients' Symptoms, All Survey Respondents 
Exhibit 2-32: Prostatitis Patients' Symptoms, by Survey Respondent Age Group 
Exhibit 2-33: Prostatitis Patients' Symptoms, by Practice Type 
Exhibit 2-34: Prostatitis Patients' Symptoms, by Patient Volumes 
Exhibit 2-35: Prostatitis Patients' Symptoms, by Geographical Region 

3. FEMALE URINARY INCONTINENCE MANAGEMENT

3.1 Obstacles to the Widespread Treatment of Female Urinary Incontinence
3.2 Urinary Incontinence Treatments
	3.2.1 Effectiveness of Urinary Incontinence Treatments
	3.2.2 Familiarity with Urinary Incontinence Treatments
	3.2.3 Current and Planned Use of Urinary Incontinence Treatments
3.3 Urodynamics Equipment
	3.3.1 Current and Planned Urodynamics Equipment Ownership

Exhibit 3-1: Obstacles to the Widespread Treatment of Female Urinary Incontinence by Urologists, All Survey Respondents 
Exhibit 3-2: Factors Rated "Major Obstacle" to the Widespread Treatment of Female Urinary Incontinence by Urologists, by Survey Respondent Age Group 
Exhibit 3-3: Factors Rated "Major Obstacle" to the Widespread Treatment of Female Urinary Incontinence by Urologists, by Practice Type 
Exhibit 3-4: Factors Rated "Major Obstacle" to the Widespread Treatment of Female Urinary Incontinence by Urologists, by Patient Volumes 
Exhibit 3-5: Factors Rated "Major Obstacle" to the Widespread Treatment of Female Urinary Incontinence by Urologists, by Geographical Region
Exhibit 3-6: Rated Effectiveness of Urinary Incontinence Treatments, All Survey Respondents 
Exhibit 3-7: Rated Effectiveness of Urinary Incontinence Treatments, by Survey Respondent Age Group 
Exhibit 3-8: Rated Effectiveness of Urinary Incontinence Treatments, by Practice Type 
Exhibit 3-9: Rated Effectiveness of Urinary Incontinence Treatments, by Patient Volumes 
Exhibit 3-10: Rated Effectiveness of Urinary Incontinence Treatments, by Geographical Region 
Exhibit 3-11: Shares of Urologists Not Familiar with Urinary Incontinence Treatments, All Survey Respondents 
Exhibit 3-12: Shares of Urologists Not Familiar with Urinary Incontinence Treatments, by Survey Respondent Age Group 
Exhibit 3-13: Shares of Urologists Not Familiar with Urinary Incontinence Treatments, by Practice Type 
Exhibit 3-14: Shares of Urologists Not Familiar with Urinary Incontinence  Treatments, by Patient Volumes 
Exhibit 3-15: Shares of Urologists Not Familiar with Urinary Incontinence Treatments, by Geographical Region 
Exhibit 3-16: Current and Planned Use of Urinary Incontinence Treatments, All Survey Respondents 
Exhibit 3-17: Current and Planned Use of Major Urinary Incontinence Surgery, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical Region 
Exhibit 3-18: Current and Planned Use of Minimally Invasive Urinary Incontinence Surgery, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical 
Region 
Exhibit 3-19: Current and Planned Use of Resorbable Bulking Agents, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical Region 
Exhibit 3-20: Current and Planned Use of Nonresorbable Bulking Agents, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical Region 
Exhibit 3-21:Current and Planned Use of Radiofrequency Bladder Neck Suspension, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical Region 
Exhibit 3-22: Current and Planned Use of Extracorporeal Magnetic Innervation, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical Region 
Exhibit 3-23: Current and Planned Ownership of Urodynamics Equipment, All Survey Respondents 
Exhibit 3-24: Current and Planned Ownership of Urodynamics Equipment, by Survey Respondent Age Group 
Exhibit 3-25: Current and Planned Ownership of Urodynamics Equipment, by Practice Type 
Exhibit 3-26: Current and Planned Ownership of Urodynamics Equipment, by Patient Volumes 
Exhibit 3-27: Current and Planned Ownership of Urodynamics Equipment, by Geographical Region 
Exhibit 3-28: Urodynamics Systems that Survey Respondents Currently Own or Plan to Purchase, by Manufacturer 


4. PROSTATE CANCER MANAGEMENT

4.1 First-Year Treatment Protocols
4.2 Challenges Associated with Prostate Cancer Management
4.3 Transrectal Ultrasound Equipment
	4.3.1 Current and Planned Transrectal Ultrasound Equipment Ownership

Exhibit 4-1: Distribution of Prostate Cancer Patients by Treatment Modality for the Years 2001 and 2003, All Survey Respondents 
Exhibit 4-2: Distribution of Prostate Cancer Patients by Treatment Modality for the Years 2001 and 2003, by Survey Respondent Age Group  
Exhibit 4-3: Distribution of Prostate Cancer Patients by Treatment Modality for the Years 2001 and 2003, by Practice Type 
Exhibit 4-4: Distribution of Prostate Cancer Patients by Treatment Modality for the Years 2001 and 2003, by Patient Volumes 
Exhibit 4-5: Distribution of Prostate Cancer Patients by Treatment Modality for the Years 2001 and 2003, by Geographical Region 
Exhibit 4-6: Challenges Associated with Prostate Cancer Management, All Survey Respondents 
Exhibit 4-7: Factors Rated "Major Challenge" or "Moderate Challenge" to the Treatment of Prostate Cancer, by Survey Respondent Age Group 
Exhibit 4-8: Factors Rated "Major Challenge" or "Moderate Challenge" to the Treatment of Prostate Cancer, by Practice Type 
Exhibit 4-9: Factors Rated "Major Challenge" or "Moderate Challenge" to the Treatment of Prostate Cancer, by Patient Volumes 
Exhibit 4-10: Factors Rated "Major Challenge" or "Moderate Challenge" to the Treatment of Prostate Cancer, by Geographical Region  
Exhibit 4-11: Current and Planned Ownership of Transrectal Ultrasound Equipment, All Survey Respondents 
Exhibit 4-12: Current and Planned Ownership of Transrectal Ultrasound Equipment, by Survey Respondent Age Group 
Exhibit 4-13: Current and Planned Ownership of Transrectal Ultrasound  Equipment, by Practice Type 
Exhibit 4-14: Current and Planned Ownership of Transrectal Ultrasound  Equipment, by Patient Volumes 
Exhibit 4-15: Current and Planned Ownership of Transrectal Ultrasound  Equipment, by Geographical Region 
Exhibit 4-16: Transrectal Ultrasound Equipment Mentions, All Survey Respondents 
Exhibit 4-17: Transrectal Ultrasound Equipment Manufacturer Mentions, by Survey Respondent Age Group 
Exhibit 4-18: Transrectal Ultrasound Equipment Manufacturer Mentions, by Survey Respondent Practice Type 
Exhibit 4-19: Transrectal Ultrasound Equipment Manufacturer Mentions, by Survey Respondent Patient Volumes 
Exhibit 4-20: Transrectal Ultrasound Equipment Manufacturer Mentions, by Geographical Region  


5. ERECTILE DYSFUNCTION MANAGEMENT

5.1 Effectiveness of Erectile Dysfunction Treatments
5.2 Familiarity with Erectile Dysfunction Treatments
5.3 Current and Planned Use of Erectile Dysfunction Treatments
5.4 Types of Patients Treated with Oral Erectile Dysfunction Drugs

Exhibit 5-1: Rated Effectiveness of Erectile Dysfunction Treatments, All Survey Respondents 
Exhibit 5-2: Rated Effectiveness of Erectile Dysfunction Treatments, by Survey Respondent Age Group 
Exhibit 5-3: Rated Effectiveness of Erectile Dysfunction Treatments, by Practice Type 
Exhibit 5-4: Rated Effectiveness of Erectile Dysfunction Treatments, by Patient Volumes 
Exhibit 5-5: Rated Effectiveness of Erectile Dysfunction Treatments, by Geographical Region 
Exhibit 5-6: Shares of Urologists Not Familiar with Erectile Dysfunction Treatments, All Survey Respondents 
Exhibit 5-7: Shares of Urologists Not Familiar with Erectile Dysfunction Treatments, by Survey Respondent Age Group 
Exhibit 5-8: Shares of Urologists Not Familiar with Erectile Dysfunction Treatments, by Practice Type 
Exhibit 5-9: Shares of Urologists Not Familiar with Erectile Dysfunction Treatments, by Patient Volumes 
Exhibit 5-10: Shares of Urologists Not Familiar with Erectile Dysfunction Treatments, by Geographical Region 
Exhibit 5-11: Current and Planned Use of Erectile Dysfunction Treatments, All Survey Respondents 
Exhibit 5-12: Current and Planned Use of Topical Alprostadil Formulations, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical Region 
Exhibit 5-13: Current and Planned Use of Cialis, by Survey Respondent Age  Group, Practice Type, Patient Volumes, and Geographical Region  
Exhibit 5-14: Current and Planned Use of Vardenafil, by Survey Respondent  Age Group, Practice Type, Patient Volumes, and Geographical Region 
Exhibit 5-15: Types of Patients Treated with Oral Erectile Dysfunction Drugs for the Years 2001 and 2003, All Survey Respondents 
Exhibit 5-16: Shares of Patients Treated with Oral Erectile Dysfunction Drugs to Improve/Enhance Sexual Performance for the Years 2001 and 2003, by Survey Respondent Age 
Group, Practice Type, Patient Volumes, and Geographical Region 

6. DEVELOPMENTS IMPACTING UROLOGIC PRACTICE

6.1 Important Developments in Urologic Practice
6.2 Selected Companies Serving the Urology Products Market
	6.2.1 American Medical Systems
	6.2.2 C.R. Bard
	6.2.3 Boston Scientific
	6.2.4 Circon
	6.2.5 Cook
	6.2.6 Johnson & Johnson
	6.2.7 Mentor
	6.2.8 Karl Storz
	6.2.9 Timm Medical Technologies
	6.2.10 Urologix

Exhibit 6-1: Developments Expected to Have the Greatest Impact on Urologic Practice Over the Next Two to Three Years, All Survey Respondents 
Exhibit 6-2: Urology Device Manufacturer Ratings, All Survey Respondents 
Exhibit 6-3: Shares of Survey Respondents Not Familiar with Selected Urology Device Manufacturers 
Exhibit 6-4: Ratings for American Medical Systems, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical Region 
Exhibit 6-5: Lack of Familiarity with American Medical Systems, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical Region 
Exhibit 6-6: Ratings for C.R. Bard, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical Region 
Exhibit 6-7: Lack of Familiarity with C.R. Bard, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical Region 
Exhibit 6-8: Ratings for Boston Scientific, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical Region 
Exhibit 6-9: Lack of Familiarity with Boston Scientific, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical Region 
Exhibit 6-10: Ratings for Circon, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical Region 
Exhibit 6-11: Lack of Familiarity with Circon, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical Region 
Exhibit 6-12: Ratings for Cook, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical Region 
Exhibit 6-13: Lack of Familiarity with Cook, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical Region 
Exhibit 6-14: Ratings for Johnson & Johnson, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical Region 
Exhibit 6-15: Lack of Familiarity with Johnson & Johnson, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical Region 
Exhibit 6-16: Ratings for Mentor, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical Region 
Exhibit 6-17: Lack of Familiarity with Mentor, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical Region 
Exhibit 6-18: Ratings for Karl Storz, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical Region 
Exhibit 6-19: Lack of Familiarity with Karl Storz, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical Region 
Exhibit 6-20: Ratings for Timm Medical Technologies, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical Region
Exhibit 6-21: Lack of Familiarity with Timm Medical Technologies, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical Region  
Exhibit 6-22: Ratings for Urologix, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical Region 
Exhibit 6-23: Lack of Familiarity with Urologix, by Survey Respondent Age Group, Practice Type, Patient Volumes, and Geographical Region  
 
COMPANY LISTING


Contact Us

Need help finding medtech research? Let us help you!